Short Communication

Human β-defensin 3 increases the TLR9-dependent response to bacterial DNA

Sarah L. McGlasson¹, Fiona Semple¹, Heather MacPherson¹, Mohini Gray², Donald J. Davidson² and Julia R. Dorin¹,²

¹ MRC Human Genetics Unit, IGMM, University of Edinburgh, Edinburgh, UK
² MRC Centre for Inflammation Research, QMRI, University of Edinburgh, Edinburgh, UK

Human β-defensin 3 (hBD3) is a cationic antimicrobial peptide with potent bactericidal activity in vitro. HBD3 is produced in response to pathogen challenge and can modulate immune responses. The amplified recognition of self-DNA by human plasmacytoid dendritic cells has been previously reported, but we show here that hBD3 preferentially enhances the response to bacterial DNA in mouse Flt-3 induced dendritic cells (FLDCs) and in human peripheral blood mononuclear cells. We show the effect is mediated through TLR9 and although hBD3 significantly increases the cellular uptake of both E. coli and self-DNA in mouse FLDCs, only the response to bacterial DNA is enhanced. Liposome transfection also increases uptake of bacterial DNA and amplifies the TLR9-dependent response. In contrast to hBD3, lipofection of self-DNA enhances inflammatory signaling, but the response is predominantly TLR9-independent. Together, these data show that hBD3 has a role in the innate immune-mediated response to pathogen DNA, increasing inflammatory signaling and promoting activation of the adaptive immune system via antigen presenting cells including dendritic cells. Therefore, our data identify an additional immunomodulatory role for this copy-number variable defensin, of relevance to host defence against infection and indicate a potential for the inclusion of HBD3 in pathogen DNA-based vaccines.

Keywords: Antimicrobial peptide · β-Defensin · Dendritic cells · Plasmacytoid dendritic cells · Toll like receptor 9 · Type I interferon

Additional supporting information may be found in the online version of this article at the publisher’s web-site

Introduction

Antimicrobial peptides (AMP) such as defensins and the cathelicidin LL-37 were initially characterized as potent bactericidal agents in vitro. AMP are now also recognized as important immunomodulatory molecules, hence the term host defence peptide (HDP) is now widely used [1, 2]. HDP are cationic peptides with amphipathic structures enabling them to rapidly enter cells [3–5]. The expression of β-defensins at mucosal surfaces is minimal until triggered by pathogen- or damage-associated molecular patterns (PAMP/DAMP) or inflammation [6, 7]. HDP have been shown to modulate the host responses to nucleic acids. Both LL-37 and human β-defensin 3 (hBD3) have been shown to amplify the type I interferon response to viral dsRNA, via the MAVS pathway in keratinocytes, and through MDA5/MAVS in macrophages [3, 8]. LL-37, complexed with endogenous self-DNA, enhances activation of the cytoplasmic pattern recognition receptor stimulator of interferon genes in monocytes and TLR9 in
human plasmacytoid dendritic cells (pDCs), resulting in a significant increase in production of the type I interferon, IFN-α [9]. Similarly, hBD3 has recently been shown to precipitate condensation of human self-DNA, increasing its entry into pDCs and triggering IFN-α production [10]. Furthermore, hBD2 and hBD3 can enhance the uptake of self-DNA and promote DNA-induced IFN-α expression in human pDCs [11]. These immunomodulatory properties of HDP have implicated their involvement in the pathogenesis of autoimmune diseases including psoriasis, systemic lupus erythematosus, and type 1 diabetes [10, 12, 13]. Increased copy number of the hyper copy number variable human β-defensin locus has been associated with psoriasis [14]. However, bacterial infection is a relatively common occurrence compared to development of autoimmune disease. This highlights the importance of investigating the previously undescribed effect of hBD3 on the response to bacterial DNA. Production of hBD3 at the site of infection results in bacterial cell wall disruption and osmotic lysis, leading to release of cytoplasmic contents, including DNA [15, 16]. The increased response of antigen presenting cells to pathogen DNA in the presence of hBD3 would promote the functional activation of other immune cells involved in host defence. Therefore, we sought to determine the cellular response of mouse and human antigen presenting cells to bacterial DNA in the presence of hBD3 as would be encountered in an infection setting.

We show here that hBD3 significantly amplified the response to bacterial DNA in both mouse and human immune cells in a TLR9-dependent manner. This demonstrates a further important aspect of protection from infection afforded by defensins and suggests that this property of hBD3 could be utilized to increase efficacy of DNA-based vaccines.

Results and discussion

hBD3 enhances the immune response to bacterial DNA in murine FLDCs and human PBMCs

The effect of hBD3 on the immune response to bacterial DNA, such as would be released by AMP-mediated killing during infection was investigated in murine Flt-3 ligand-induced bone marrow-derived dendritic cell cultures (FLDCs), comprising a mixed population of conventional DCs (cDCs) and plasmacytoid DCs (pDCs). FLDCs have been widely used to study the innate immune response to nucleic acids [11, 17, 18]. cDCs and pDCs are identifiable by expression of CD11c and B220 and activation of the populations can be independently assessed (Supporting Information Fig. 1). pDCs (CD11c+ B220high), constitute approximately 10–20% of FLDCs and are specialized to rapidly produce large amounts of IFN-α in response to particular immune stimuli, due to increased expression and rapid activation of the transcription factor IFN regulatory factor 7, by a pDC-specific MyD88-dependent pathway [19, 20].

As expected, treatment of murine FLDCs with 1 μg/mL E. coli-DNA resulted in upregulation of costimulatory molecules and production of IFN-α and IL-6 (Fig. 1A and B). We confirmed that the response to E. coli-DNA was not caused by another bacterial contaminant in the DNA preparation (Supporting Information Fig. 2).

hBD3 alone had no effect on cytokine expression, cell surface marker expression or viability of FLDCs at the concentration used throughout this study (Supporting Information Fig. 3). However, 5 μg/mL hBD3 (1 μM) in combination with E. coli-DNA resulted in a significant increase in the production of IFN-α and IL-6 and the expression of costimulatory molecules by murine FLDCs compared with bacterial DNA alone (Fig. 1A and B and Supporting Information Fig. 4). We additionally show that hBD3 combined with bacterial DNA, significantly increased the production of CXCL10 (a cytokine induced by type I interferon and reflects activation of pDCs [21]) by human ex vivo PBMCs (Fig. 1C). It is therefore likely that the bacterial DNA-induced cytokine release we observe in human (as in mouse) is due to TLR9 activation of pDCs in the total PBMC population. This has previously been shown with CpG in human pDCs isolated from peripheral blood [22]. Human cDCs do not express TLR9 [22] but other immune cells in human PBMCs do express TLR9 (NK cells; B cells; CD4+ and CD8+ T cells and predominantly CD14 monocytes [23]) and these may also be activated and contribute to the increased cytokine release we observe with bacterial DNA in combination with hBD3.

hBD3 enhances the immune response to self-DNA only in human PBMCs

It has been previously reported that self-DNA alone does not induce any response in human pDCs. However liposome transfection [24] or complexing to HDP (including hBD3) increases the IFN-α response to self-DNA in human pDCs [10, 11]. Schmidt et al. showed that various cationic molecules enable endosomal localization of self-DNA, thereby increasing access to endosomal TLR9 in human pDCs [25]. However only molecules of a certain size enabled optimal inter-DNA spacing allowing multiple TLR9 interactions and activation that correlated with an increased interferon response and hBD3 allowed optimal arrangement of DNA ligand and human TLR9 [25]. In agreement with these publications, we see an increase in CXCL10 in human pDCs treated with self-DNA and hBD3 compared to self-DNA alone. In contrast, in mouse FLDCs, self-DNA did not stimulate an immune response and hBD3 did not influence this (Fig. 1A–C). Defb14 is the clear orthologue of DEFB103 (hBD3) despite being only 64% identical and we have previously demonstrated that its bactericidal and chemoattractant abilities are fundamentally similar [26]. In addition, Barabas et al. have shown that mouse bone marrow derived macrophages exposed to Defb14 reveal an exacerbated response to various TLR ligands, including CpG that is known to activate TLR9. This implies that the increased TLR9 response to bacterial DNA by these defensin peptides is conserved between human and mouse [27]. However, the species difference in the influence of hBD3 on the response of pDCs to self-DNA may reflect the differences between human and mouse in the ability of TLR9 to recognize mammalian DNA [28].
The increased immune response of FLDCs to bacterial DNA in the presence of hBD3 is mediated by TLR9

We used TLR9"/" FLDCs to test whether the hBD3-mediated amplification of the immune response of FLDCs to bacterial DNA was due to increased activation of TLR9, or due to activation of an alternative cytoplasmic pattern recognition receptor, as we have previously shown with hBD3 and poly(I:C)) [3]. Endosomal TLR9 is activated by bacterial DNA due to the presence of unmethylated CpG residues, and can also sense the phosphodiester DNA backbone of unmodified single-stranded DNA in a CpG-independent manner [29, 30]. FLDCs treated with in vitro methylated E. coli-DNA showed a significant reduction in the inflammatory response compared to exposure to untreated E. coli-DNA (Supporting Information Fig. 5) consistent with TLR9 involvement. In addition, the cytokine response to bacterial DNA with or without hBD3 was ablated in TLR9"/" FLDCs (Fig. 2A). These results confirm that the increased response of FLDCs to bacterial DNA when in the presence of hBD3 is mediated through TLR9.

We showed that self-DNA could only stimulate an immune response in FLDCs when transfected (Fig. 2B). This response to transfected self-DNA was shown to be almost entirely TLR9-independent implicating an alternative receptor in the response of FLDCs to transfected self-DNA (Fig. 2B). This is in contrast, to the
Figure 2. The effect of hBD3 on the response to E. coli-DNA in mouse FLDCs is TLR9 dependent. Mouse FLDCs from WT or TLR9 deficient (TLR9−/−) mice were incubated with E. coli-DNA with or without hBD3. Supernatants were collected and cytokine secretion was assayed by ELISA (A). Mouse FLDCs from WT or TLR9 deficient (TLR9−/−) mice were incubated or transfected with E. coli- or self-DNA. Supernatants were collected and cytokine secretion was assayed by ELISA (B). The response to TLR4 ligand LPS was intact in both WT and TLR9−/−FLDC (and reduced in the presence of hBD3 as expected [31](Supporting Information Fig.6), Data are shown as mean ± SEM and are pooled from three or more independent experiments performed in triplicate. *p < 0.05, **p < 0.01 unpaired t-test.

**Innate immunity**

**hBD3 increases uptake of labeled E. coli-DNA and self-DNA into FLDCs**

We next sought to understand the mechanistic basis for the effect of hBD3 on the response to bacterial DNA. An electrophoretic mobility shift assay demonstrated that hBD3 prevented migration of DNA into an agarose gel in concentration-dependent manner (Supporting Information Fig. 7). This suggests that, in vitro, hBD3 causes DNA to aggregate into a complex large enough to prevent migration into a gel.

We used fluorescently labeled E. coli-DNA to further investigate the effect hBD3 has on the cellular uptake of bacterial DNA. Flow cytometry demonstrated that hBD3 increased uptake of fluorescently labeled bacterial DNA by FLDCs, (Fig. 3A (MFI)). Interestingly, the proportion of cells taking up fluorescently labeled self-DNA was also significantly increased in the presence of hBD3 (Fig. 3A (%Rhodamine+)) suggesting that, despite hBD3 increasing uptake of bacterial and self-DNA, self-DNA is intrinsically nonimmunogenic in mouse FLDCs and does not activate any immune receptors in these cells.

We additionally observed by microscopy that hBD3 treatment appeared to result in DNA aggregation in FLDCs compared with a more diffuse pattern in the absence of hBD3 (Fig. 3C, white arrows). This corresponds with the results from the gel shift assay. These data indicate that hBD3 increases the response to E. coli-DNA by increasing cellular uptake, leading to increased activation of TLR9 and a consequent increase in costimulatory marker expression and cytokine production.

**Concluding remarks**

In summary, we show that in both mouse and human immune cells the antimicrobial host defence peptide hBD3 amplifies the response to bacterial DNA, eliciting increased expression of
Figure 3. hBD3 causes increased uptake of labeled E. coli- and self-DNA into mouse FLDCs and aggregation of DNA. Mouse FLDCs were incubated or transfected with rhodamine-labeled E. coli-DNA or rhodamine-labeled self-DNA with or without hBD3, or lipofection. Cell uptake was assayed by flow cytometry. Representative flow plots show gating of Rhodamine+ cells. DNA uptake was quantified by measuring proportion of rhodamine+ cells and MFI following incubation of cells with labeled DNA and hBD3 (A) or lipofectamine. (B) Data are shown as mean ± SD and are pooled from two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.005 unpaired t-test. Uptake of labeled E. coli-DNA was visualized by fluorescence and differential interference contrast microscopy. White arrow indicates intracellular labeled E. coli-DNA, in contrast to white arrow head indicating extracellular DNA (C). Scale bar = 400 μm. Images are from a single experiment representative of two independent experiments.

costimulatory markers and inflammatory cytokines, including type I interferons. The hBD3 gene, DEFB103, is present in a highly copy number variable locus in humans and copy number of this locus correlates with systemic peptide expression [32]. Our work here suggests that copy number may influence the individual’s response to infection. Additionally, this work highlights future potential for hBD3 as a TLR9 agonist for novel DNA-based vaccine therapeutics, acting by sensitizing the immune response, particularly to pathogen components.

Materials and methods

Antibodies and reagents

E. coli genomic DNA (InvivoGen) was used at 1 μg/mL. Mouse genomic DNA was used at 1 μg/mL. hBD3 (Peptide Institute) was used at 5 μg/mL. Lipofectamine LTX (ThermoFisher) was used as per manufacturer’s instructions.
The following antibodies were used for flow cytometry: CD11c-APC-eFluor780 (eBioscience), B220-eFluor450 (eBioscience), CD80-APC (eBioscience), CD86-AlexaFluor488 (Biolegend), CD40-PE (BD Bioscience), MHCII-PerCP-Cy5.5 (Biolegend).

Murine IL-6 and human IP-10 were quantified using Duoset kits (R&D). Murine IFN-α was quantified using the following: Rat anti-mouse IFN-α MAb (capture antibody), Rabbit anti-mouse IFN-α-PAb (detection antibody), Recombinant mouse IFN-α A (standard) (all PBL Interferon Source), HRP-conjugated donkey anti-rabbit (secondary antibody, Jackson Immunoresearch).

DNA was fluorescently labelled using the Label-IT nucleic acid labeling kit (MirusBio).

Cell viability was measured by quantifying lactate dehydrogenase (LDH) activity in cell supernatants using an LDH-cytotoxicity assay kit (Biovision).

The effect of hBD3 on migration of DNA into an agarose gel was determined by incubating hBD3 and DNA and running the entire reaction into a low percentage (0.5%) agarose gel containing ethidium bromide. The gel was poststained with Coomassie Blue.

FLDC isolation and culture

Bone marrow was extracted from the femurs of 8–12 week old wild-type C57B16/J mice or TLR9−/− mice (with littermates as controls) [29] and cultured with Flt-3L (200 ng/mL, Peprotech) for 8 days. Animal studies were covered by a Project License, granted by the UK Home Office under the Animal Scientific Procedures Act 1986, and locally approved by the University of Edinburgh Ethical Review Committee.

PBMC isolation

PBMCs were isolated from peripheral blood of adult donors using Ficoll gradient and plated for immediate treatment. Human venous blood was collected with written patient consent from healthy volunteers according to Lothian Research Ethics Committee approvals under AMREC Reference number 15-HV-013.

Cell stimulation

Cells were harvested and plated at 2.5 × 10^6 cells/mL, and incubated with ligands for 18–24 h. Supernatants were collected for analysis by ELISA. Cells were collected and stained for analysis by flow cytometry. Data were acquired using FACS Aria II (BD Biosciences) and analyzed using FlowJo v.9/10. For fluorescent microscopy, cells were treated for 4 h then harvested and attached to poly-lysine slides. Cells were fixed in 4% PFA and mounted using Vectashield with DAPI (VECTOR laboratories).

Statistical tests

Unpaired Student’s t-tests were performed unless otherwise stated, calculated using GraphPad Prism Software version 6/7 (La Jolla, USA). Significance levels are denoted in figures as: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, n.s. not significant.

Acknowledgments: We would like to thank Dr. Gareth Hardisty for assistance with PBMC isolation, Joanne Simpson for assistance with TLR9−/− bone marrow extraction and Elizabeth Freyer for FACS technical support. S.L.M. held an MRC studentship (MC_ST_UU10002) under supervision by J.R.D. and Prof. Andrew Jackson, MRC Human Genetics Unit, IGMM, University of Edinburgh. D.J.D. was supported by a Medical Research Council (http://www.mrc.ac.uk) Senior Non-clinical Fellowship (G1002046). J.R.D. conceived of the study and J.R.D., S.L.M., and D.J.D. interpreted the data and contributed to writing manuscript. M.G. provided access to TLR9−/− mice. S.L.M., H.M., and F.S. carried out the experimental procedures and analyzed data.

Conflict of interest: The authors declare no financial or commercial conflict of interest.

References

1. Semple, F. and Dorin, J. R., Beta-defensins: multifunctional modulators of infection, inflammation and more? J. Innate Immun. 2012. 4: 337–347.
2. Suarez-Carmona, M., Hubert, P., Delvenne, P. and Herfs, M., Defensins: “simple” antimicrobial peptides or broad-spectrum molecules? Cytokine Growth Factor Rev. 2015. 26: 361–370.
3. Semple, F., MacPherson, H., Webb, S., Kilanowski, F., Lettice, L., McGlashon, S. L., Wheeler, A. P. et al., Human β-D-3 Exacerbates MDAS but Suppresses TLR3 Responses to the viral molecular pattern mimic polyinosinic:polycytidylic acid. PLoS Genet. 2015. 11: e1005673.
4. Chamilos, G., Gregorio, J., Meller, S., Lande, R., Kontoyiannis, D. P., Modlin, R. L. and Gilliet, M., Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood 2012. 120: 3699–3707.
5. Lau, Y. E., Rozek, A., Scott, M. G., Goosney, D. L., Davidson, D. J. and Hancock, R. E., Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun. 2005. 73: 583–591.
6. Bernard, J. J. and Gallo, R. L., Cyclooxygenase-2 enhances antimicrobial peptide expression and killing of staphylococcus aureus. J. Immunol. 2010. 185: 6535–6544.
7. Pierson, T., Learmonth-Pierson, S., Pinto, D. and van Hooik, M. L., Cigarette smoke extract induces differential expression levels of beta-defensin peptides in human alveolar epithelial cells. Tob. Induc. Dis. 2013. 11: 10.
8. Afshar, M., Martinez, A. D., Gallo, R. L. and Hata, T. R., Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C.
review and analysis of 36 cases. J. Eur. Acad. Dermatol. Venereol. 2013. 27: 771–778.
9 Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y. H., Honeyn, B., Cao, W. et al., Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007. 449: 564–569.
10 Lande, R., Chamilos, G., Gargul, D., Demaria, O., Frasca, L., Durr, S., Conrad, C. et al., Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur. J. Immunol. 2015. 45: 203–213.
11 Tewary, P., de la Rosa, G., Sharma, N., Rodrigues, L. G., Tarasov, S. G., Howard, O. M., Shiroti, H. et al., β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation. J. Immunol. 2013. 191: 865–874.
12 Lande, R., Gargul, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S. et al., Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011. 3: 73ra19.
13 Diana, J., Simoni, Y., Furio, L., Beaudoin, L., Agerberth, B., Barrat, F. and Lehuen, A., Crosstalk between neutrophils, B1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 2013. 19: 65–73.
14 Hollo, E. J., Huffman, U., Zeeuwen, P. L., Palla, R., Laszcor, J., Rodijk-Olthuis, D., van de Kerkhof, P. C. et al., Psoriasis is associated with increased beta-defensin genomic copy number. Nat. Genet. 2008. 40: 23–25.
15 Nuding, S., Frasch, T., Schaller, M., Stange, E. F. and Zabel, L. T., Synergistic effects of antimicrobial peptides and antibiotics against clostridium difficile. Antimicrob. Agents Chemother. 2014. 58: 5719–5725.
16 Sass, V., Schneider, T., Wilmes, M., Korner, C., Tossi, A., Novikova, N., Shamova, O. et al., Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect. Immun. 2010. 78: 2793–2800.
17 Rigby, R. E., Webb, I. M., Mackenzie, K. J., Li, Y., Leitch, A., Reijns, M. A., Lundie, R. J. et al., mRNA-DNA hybrids are a novel molecular pattern sensed by TLR9. EMBO J. 2014. 33: 542–558.
18 Ryan, L. K., Dai, J., Yin, Z., Megjogorac, N., Uhlhorn, V., Yim, S., Schwartz, K. D. et al., Modulation of human beta-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity. J. Leukoc. Biol. 2011. 90: 343–356.
19 Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C. et al., Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005. 434: 1035–1040.
20 Izaguirre, A., Barnes, B. J., Amrute, S., Yeow, W. S., Megjogorac, N., Dai, J., Feng, D. et al., Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 2003. 74: 1125–1138.
21 Blackwell, S. E. and Krieg, A. M., CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J. Immunol. 2003. 170: 4061–4068.
22 Fuchsberger, M., Hochrein, H. and O’Keefe, M., Activation of plasmacytoid dendritic cells. Immunol. Cell Biol. 2005. 83: 571–577.
23 Mortezagholi, S., Babaloo, Z., Rahimzadeh, P., Ghaedi, M., Namdari, H., Assar, S., Azimi Mohamadabadi, M. et al., Evaluation of PBMC distribution and TLR9 expression in patients with systemic lupus erythematosus. Iran J. Allergy Asthma Immunol. 2016. 15: 229–236.
24 Coch, C., Busch, N., Winnenauer, V., Hartmann, E., Janke, M., Abdel-Mottaleb, M. M., Lampecht, A. et al., Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. J. Leukoc. Biol. 2009. 86: 663–670.
25 Schmidt, N. W., Jin, F., Lande, R., Curnk, T., Xian, W., Lee, C., Frasca, L. et al., Liquid-crystalline ordering of antimicrobial peptide-DNA complex controls TLR9 activation. Nat. Mater. 2015. 14: 696–700.
26 Taylor, K., Clarke, D. J., McCullough, B., Chin, W., Seo, E., Yang, D., Oppenheim, J. et al., Analysis and separation of residues important for the chemoattractant and antimicrobial activities of beta-defensin 3. J. Biol. Chem. 2008. 283: 6631–6639.
27 Barbas, N., Roßl, J., Holler, E. and Hahlgens, T., Beta-defensins activate macrophages and synergize in pro-inflammatory cytokine expression induced by TLR ligands. Immunobiology 2013. 218: 1005–1011.
28 Bauer, S., Kirschning, C. J., Härker, H., Redecke, V., Hausmann, S., Akira, S., Wagner, H. et al., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 2001. 98: 9237–9242.
29 Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M. et al., A Toll-like receptor recognizes bacterial DNA 30. Nature 2000. 408: 740–745.
30 Haas, T., Metzger, J., Schmitz, F., Heit, A., Müller, T., Latz, E. and Wagner, H., The DNA sugar backbone 2’ deoxyribose determines toll-like receptor 9 activation. Immunity 2008. 28: 315–323.
31 Semple, F., Webb, S., Li, H. N., Patel, H. B., Perretti, M., Jackson, I. J., Gray, M. et al., Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur. J. Immunol. 2010. 40: 1073–1078.
32 Jansen, P. A., Rodijk-Olthuis, D., Hollo, E. J., Kamsteeg, M., Tjabringa, G. S., de Jongh, G. J., van Vlijmen-Willems, I. M. et al., Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin 1. PLoS One 2009. 4: e4725.

**Abbreviations:**

AMP: antimicrobial peptide  
C-D: conventional dendritic cells  
HDP: host defence peptide  
HBD3: human β-defensin 3  
FLD: FLT-3 ligand induced dendritic cells  
PDC: plasmacytoid dendritic cell

Full correspondence: Dr. Julia R. Dorin, MRC Centre for Inflammation Research, University of Edinburgh Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK  
e-mail: julia.dorin@ed.ac.uk  
Tel: +44(0)131 242 6590  
Fax: +44(0)131 242 6578

Received: 8/11/2016  
Revised: 22/12/2016  
Accepted: 17/1/2017  
Accepted article online: 19/1/2017

© 2017 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. www.eji-journal.eu